SCHEMBL4909656

SCHEMBL4909656

N#Cc1c(SCC(N)=O)ncnc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 4/20 0.46
STK17B O94768 1/20 0.46
ADORA1 P30542 4/20 0.45
ADORA2B P29275 3/20 0.45
ALDH1A1 P00352 7/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899080 0.83 ALDH1A1 (0.52) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4905895 0.81 ALDH1A1 (0.47) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4911229 0.81 ADORA1 (0.48) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4905617 0.80 ADORA2B (0.49) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4907044 0.79 ADORA1 (0.48) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4908034 0.78 BACE1 (0.47) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4908636 0.78 ADORA2B (0.50) ADORA1ADORA2BALDH1A1SMN1; SMN2MEN1
SCHEMBL4908824 0.74 KMO (0.50) KMOADORA1ALOX15ADORA2A
SCHEMBL4909592 0.74 KMO (0.53) KMOADORA1ALOX15ADORA2A
SCHEMBL4900777 0.72 BRAF (0.53) STK17BADORA2BTP53MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF KMO 3826/4885STK17B 3802/4885ADORA1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.